CD8A and COVID-19: Our results are in line with Netti et al. who reported that therapy with mTOR-inhibitors, which are traditionally able to improve both quantity and quality of memory CD8+ T cells induced by viral infection and vaccination [40], allowing both better humoral and T cell-mediated immune response to COVID-19 vaccination in KT recipients [41].